Cancer diagnostics company Pacific Edge says it will seek a preliminary injunction in the US if it fails to achieve a timely revision or withdrawal of a decision against reimbursement for its Cxbladder tests.
Novitas, the Medicare Administrative Contractor with jurisdiction for its US laboratory in
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
